NanoKnife Drives AngioDynamics Growth
AngioDynamics Reports Record Q4 Revenue, Beats Estimates on Med Tech and NanoKnife Strength
Anonymous
Key Points
1
In Q4 2026 AngioDynamics posted an earnings beat with EPS of -$0.07 vs consensus -$0.09, and revenue of $86.61 million, beating estimates by about $4.6 million.
2
Institutional investor activity around ANGIODynamics was notable, with 61 institutions adding shares in Q1 2026 and 79 reducing positions; examples include Divisadero Street Capital Management (added 562,153 shares) and Bank of America (added 364,763 shares).
3
AngioDynamics initiated the AMBITION BTK and RECOVER-AV clinical trials, expanding its interventional oncology and therapeutic portfolio.
4
Palmetto GBA finalized a local coverage determination covering NanoKnife IRE for qualifying Medicare patients with prostate and liver cancer, effective July 5, 2026.
5
Management highlighted tariff-related headwinds as a factor affecting profitability, signaling ongoing macro-driven cost pressures despite medtech growth.
AngioDynamics posted record fourth-quarter and full-year results for fiscal 2026, with Q4 revenue hitting $86.6 million — an 8% jump year over year — and beating Wall Street estimates by about $4.6 million, according to QuiverQuant. Full-year revenue reached $320.2 million, driven largely by the company's fast-growing Med Tech segment.
The company also beat earnings expectations, posting an adjusted loss of $0.07 per share versus the consensus estimate of $0.09, per QuiverQuant. AngioDynamics ended fiscal 2026 with $53.9 million in cash and zero debt, and it set fiscal 2027 revenue guidance of $336 million to $341 million.
NanoKnife Wins Medicare Coverage, Fuels Med Tech Growth
NanoKnife — AngioDynamics's cancer-killing device that uses electrical pulses to destroy tumors — was a standout performer this year. The technology helped push Med Tech segment growth and remains central to the company's strategy of building in large, fast-moving markets, according to MarketScreener.
A major regulatory win landed in July 2026. Palmetto GBA, a Medicare contractor, finalized local coverage for NanoKnife procedures on qualifying patients with prostate and liver cancer, effective July 5, 2026. That coverage decision opens a significant new pool of patients who can now access the treatment through Medicare, per MarketScreener.
Seven Straight Quarters of Double-Digit Med Tech Growth
AngioDynamics delivered its seventh consecutive quarter of double-digit Med Tech growth, according to ScanX Trade. The company also reported $3.3 million in adjusted EBITDA and $17.5 million in operating cash flow for the full year. That cash generation helped the company stay debt-free heading into fiscal 2027.
Management described the results as proof that its strategic transformation is working. The company is shifting its focus toward higher-growth interventional oncology and specialty device markets. GAAP results still showed a loss of $0.27 per share for Q4, reflecting ongoing investment costs and macro headwinds like tariffs, per ScanX Trade.
New FDA-Approved Trials Expand the Clinical Pipeline
AngioDynamics received FDA Investigational Device Exemption approvals to run two new clinical trials: AMBITION BTK and RECOVER-AV. These trials expand the company's work in interventional oncology and other therapeutic areas, signaling a pipeline that goes well beyond NanoKnife, according to MarketScreener.
The FDA approvals mark a key step in proving out new devices and treatments in controlled clinical settings. Positive trial data would support future reimbursement coverage decisions — similar to the Medicare win NanoKnife just secured. That path from trial to coverage is now a proven playbook for AngioDynamics.
FY2027 Guidance Tops Estimates Amid Tariff Warnings
AngioDynamics guided for fiscal 2027 revenue of $336 million to $341 million, topping the prior Street estimate of about $329 million, per Benzinga. The company also projected adjusted EBITDA of $13 million to $16 million. Adjusted EPS is expected to land between -$0.29 and -$0.24, wider than the -$0.16 consensus estimate.
Management flagged tariff-related costs as a headwind that will pressure margins in the year ahead. Even so, institutional investors stayed active around the stock. In Q1 2026, 61 institutions added shares in AngioDynamics, including Divisadero Street Capital Management, which added 562,153 shares, and Bank of America, which added 364,763 shares, per QuiverQuant.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
23
Articles
39
Reach
62
A
AnonymousAuthor